Non Invasive (NI) Technologies

Non-Invasive Glucose Detection

Needle‑Free. Reagent‑Free. Pain‑Free.

Groundbreaking Advance: ILS has developed a non‑invasive glucose detection technology that eliminates blood draws, needles, reagent patches, and skin‑penetrating probes.

Built on ILS's proprietary DDLS Platform

Clinical Impact

  • 37 million Americans live with diabetes

  • 96 million are pre‑diabetic

  • Needle‑free monitoring improves compliance and reduces complications

Technical Foundation

Our spectroscopy platform detects biophysical changes correlated with glucose levels — without skin penetration or chemical reactions.

DDLS incorporates multi scientific and technological disciplines

Biochemical Basis

Biological cells, e.g., Red blood cells, chemically react with glucose (glycation)

  • Glycation changes cell morphology

    • Correlates to the extent of cell glycation

      • Correlates to blood glucose concentration

Biophysical Basis

THE key equation is the modified autocorrelation function, C'(t ):

  • C(t) is the time-autocorrelation function for the Brownian motion (no applied electric field);

  • C'(t) is the autocorrelation function modulated by the electric field; where:

    t is time "shift"

    q is an experimental constant

    v is the instantaneous velocity of the particles under applied field gradient

  • C'(t) is analyzed by the Fourier transform (FT)

  • peaks in the ft indicate condition of biological cell

  • peaks introduce features to resolve complex multi-component mixtures

Notes on Market and Potential Impact

  • CGM: Market evaluated between $20-$40 Billion, driven by diabetes.

  • The Non-Invasive Diagnostics Paradigm: For glucose, the targets a multi-billion dollar vacuum. By leveraging dielectric signatures via DDLS rather than struggling with standard optical scattering or near-infrared limitations, The technology effectively hold the keys to a true non-invasive consumer and clinical device category.

  • Cancer Cell Detection & Liquid Biopsy: Applying DDLS to oncology (such as isolating or profiling circulating tumor cells, rare cell phenotypes, or macromolecular shifts in biofluids based on polarizability) targets the booming liquid biopsy and early-detection markets. Standard oncology diagnostics rely heavily on expensive genomic sequencing or affinity-based capture methods that can miss heterogeneous or rare cells. A label-free, physical-property-driven detection method changes the economics and speed of screening entirely.

  • Although continuous glucose monitor (CGM) devices reduce how often the skin must be punctured, they still require reagent patches and a probe (needle) inserted into the patient's body, which must be replaced regularly. By contrast, ILS devices need neither needles nor reagent patches.